OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company’s chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference in Boston.
Jacob will speak at the GPCRs-Targeted Drug Discovery Summit on May 22, where he’ll share the latest data on urcosimod, a treatment in development for neuropathic corneal pain - a chronic eye condition that causes severe discomfort and currently has no approved therapies.
Neuropathic corneal pain, or NCP, is believed to result from nerve damage and inflammation in the cornea. Current treatments are largely off-label and often fail to provide relief.
Urcosimod, formerly known as OK-101, is designed to reduce inflammation and pain by targeting a receptor found on certain immune and nerve cells in the eye.
In earlier trials, the drug showed promising results in reducing symptoms of dry eye disease and has just completed a Phase 2 trial in patients with NCP.
OKYO Pharma, listed on the Nasdaq, is a clinical-stage company focused on treatments for inflammatory and nerve-related eye disorders.